Management Consulting

Portfolio Management

Financial solutions tailored to your business goals

Benefit from customized solutions aimed at optimizing returns and managing risks through asset prioritization and diversification in adjacent markets with Alira Health Portfolio Management.

A proprietary methodology backed by experience

Many of our clients structure their company around a specific platform to develop many assets in very different markets. And while spreading risk over several assets is always positive, as companies face resource shortages, they need to focus on a limited number of opportunities with increased probabilities of success to convince investors.

To meet those needs, Alira Health has developed a proprietary methodology and associated tools to allow our clients to prioritize assets and define an investment strategy that ensures operational success and value creation.

Why choose Alira Health?

With Alira Health as your partner, you will benefit from:

  • An integrated team with experience across the product lifecycle
  • Proprietary digital tools tailored to your business needs
  • Click here to see our approach in action for a leading pharmaceutical company

Connect with a Winning Team

See why Alira Health was named one of the world’s best management consulting firms by Forbes.

Related news

Publications September 19, 2023
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
CDMO Pharma
News August 31, 2023
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Life Sciences MedTech Pharma
Publications August 1, 2023
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
EU Pharma Regulatory
Publications July 25, 2023
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Market Access Pharma
Blog July 24, 2023
What EU Companies Need to Know about the U.S. Inflation Reduction Act
We spoke with our inhouse experts to learn about the significance of the US Inflation Reduction Act for EU pharma and biotech companies.
Biotech Drug Development Pharma
Publications July 11, 2023
Mid-size Pharma Accelerates Early Clinical Trial Engagement of Patients with A Rare Neurological Disease
A mid-size pharma company sought an experienced advisor who could help them engage patients for an open-label extension clinical study in a rare neurological disease.
Clinical Trials Patient Engagement Pharma Rare Disease
Publications July 10, 2023
The EU Pharmaceutical Package: Regulatory Protection Changes
Our regulatory experts present a more detailed analysis of the proposed changes introduced to Regulatory Data Protection (RDP).
EU Pharma Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.